Table 4

Immunohistochemical scoring (mean) of lymph nodes in IL-12 treated (n = 10) and control patients (n = 10)

MarkerCell typeIL-12 treated mean (SD), n = 10Control mean (SD), n = 10P
CD3 (%)T cell29.5 (7.9)32.1 (10.8)
CD4 (%)T helper cell, macrophage48.2 (14.1)47.6 (12.6)
CD8 (n/mm2)T cytotoxic cell2025 (748)2016 (627)
CD20 (%)B cell49.5 (12.4)44.5 (10.4)
CD79a (%)B cell and plasma cell29.9 (10.6)25.7 (11.3)
CD56 (n/mm2)NK cell106 (57)78 (51)
CD57 (n/mm2) (outside SF)NK cell and subset of T cells168 (89)140 (91)
CD68 (%)Macrophage4.8 (3.2)3.1 (1.0)
CD21 (%)DC, FDC0.3 (0.3)0.5 (0.4)
DC-SIGN (%)DC, immature7.2 (6.4)10.4 (8.3)
DC-LAMP (n/mm2)DC, mature100 (71)292 (168)<0.005
Langerin (n/mm2)DC, Langerhans42.0 (52.0)53.4 (61.1)
CD11c (%)DC, granulocyte, macrophage19.5 (8.5)13.6 (4.6)
ICAM-2 (%)Endothelium and stromal2.5 (1.1)7.3 (3.1)<0.001
Neutrophil elastase (n/mm2)Neutrophil208 (136)107 (44)<0.01
AA-1 (n/mm2)Mast cell47.5 (13.1)95.3 (58.2)<0.005
BMK-13 (n/mm2)Eosinophil21.1 (28.1)18.4 (12.2)
MIB (n/ mm2)proliferation1061 (368)844 (340)
  • NOTE. Part of the markers are scored by semiautomatic counting (no./mm2); others by automatic recognition of the positive stained area (% positive area/total square of the lymph node). The number of DC-LAMP+ cells and mast cells decreased, the number of neutrophils increased, and the area of ICAM-2+ cells decreased after IL-12 treatment.